Fingolimod

Drug Profile

Fingolimod

Alternative Names: Fingolimod hydrochloride; FTY-720; Gilenia; Gilenya; Imusera; TDI-132

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Mitsubishi Pharma Corporation; Taito
  • Developer ALS Therapy Development Institute; Mitsubishi Pharma Corporation; Mitsubishi Tanabe Pharma Corporation; Novartis
  • Class Ethanolamines; Propylene glycols; Small molecules
  • Mechanism of Action Apoptosis stimulants; Immunosuppressants; Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis; Renal transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase II Amyotrophic lateral sclerosis
  • Discontinued Chronic inflammatory demyelinating polyradiculoneuropathy; Graft-versus-host disease; Myocarditis; Optic neuritis; Renal transplant rejection; Rheumatoid arthritis; Type 1 diabetes mellitus

Most Recent Events

  • 22 Apr 2017 Novartis Pharmaceuticals terminates a phase-III clinical trial in Chronic inflammatory demyelinating polyradiculoneuropathy in Australia, USA, United Kingdom, Belgium, France, Germany, Greece, Italy, Netherlands, Poland, Spain, Norway, Czech Republic, Canada, Israel and Japan upon the recommendation of the IDMC (PO) (NCT01625182)
  • 27 Jan 2017 Discontinued - Phase-III for Chronic inflammatory demyelinating polyradiculoneuropathy in Czech Republic (PO)
  • 27 Jan 2017 Novartis has patent protection for fingolimod in USA and Europe (Novartis 20-F filed in 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top